Healthtech company Bone Health Technologies has recently been awarded its fourth patent, marking a significant milestone in the journey of its product, Osteoboost. The wearable device is at the forefront of addressing osteopenia and osteoporosis in post-menopausal women, two conditions that significantly impact bone health.

Osteoboost’s design and innovative approach have made it the first device of its kind to demonstrate a bone strength benefit in clinical trials. Its efficacy in reducing bone mass loss in post-menopausal women has been well-documented, addressing a critical need in public health. Data reveals that a majority of fragility fractures occur in patients with osteopenia, highlighting the importance of early intervention to prevent the progression to osteoporosis.

The newly awarded patent for Osteoboost identifies it as a wearable designed specifically for the treatment and prevention of osteopenia or osteoporosis. The device operates by sending low-frequency vibrations to the targeted area, stimulating bone growth and preserving bone mineral density. These vibrations are delivered through pieces secured laterally to the user, with their intensity and frequency monitored and regulated by multiple accelerometers.

“Over 63 million Americans have low bone density, yet the field has been lacking new therapies with no new agents in clinical trials – innovations such as Osteoboost are critical to turning around the public health trajectory of fractures,” said Laura Yecies, CEO of Bone Health Technologies.

“My motivation to invent a novel solution for low bone density resulted directly from my experience treating so many patients with painful vertebral compression fractures.  I was determined to develop a non-drug treatment that patients would be interested in using and could incorporate into their daily lives to prevent the loss of bone that results in fractures,” according to Dr. Shane Mangrum, Founder, of Bone Health Technologies.

The company has made significant regulatory progress, recently filing for Class 2 Prescription De Novo Approval with the FDA and receiving Breakthrough Device Status. Findings from their clinical trial, presented at ASBMR 2023 and ENDO 2023, showcased Osteoboost’s effectiveness in mitigating bone strength decline in post-menopausal women through a double-blinded, sham-controlled design.

Show CommentsClose Comments

Leave a comment